✦ LIBER ✦

Advances in the treatment of depression

✍ Scribed by Holtzheimer, Paul E. ;Nemeroff, Charles B.

Book ID: 103869432
Publisher: American Society for Experimental NeuroTherapeutics
Year: 2006
Tongue: English
Weight: 141 KB
Volume: 3
Category: Article
ISSN: 1545-5343
DOI: 10.1016/j.nurx.2005.12.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Advances in the treatment of depression in older adults

✍ Melinda S. Lantz 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 111 KB

Double-blind comparison of fluoxetine an

Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: A pilot study

✍ Jennifer A. J. Schwartz; J. Stephen McDaniel 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB 👁 2 views

A double-blind, placebo-controlled study was conducted to assess the relative efficacy and tolerability of fluoxetine and desipramine in depressed, human immunodeficiency virus (HIV)-positive women. Although difficulty in the recruitment and retention of participants led to insufficient power to det

Recent advances in poststroke depression

✍ Haresh M. Tharwani; Pavan Yerramsetty; Paolo Mannelli; Ashwin Patkar; Prakash Ma 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 156 KB

Recent advances in the pharmacotherapy o

Recent advances in the pharmacotherapy of major depression

✍ Carol A. Glod 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 874 KB

Major depression and its pharmacotherapy have changed substantially during the last decade. Several new agents have been approved for clinical use, and psychiatric nurses must be aware of the benefits and potential adverse reactions associated with each. Moreover, more than 40 states now grant presc

Exercise in the treatment of depression

✍ Tracy L. Greer; Madhukar H. Trivedi 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 243 KB

Cilobamine in the treatment of atypical

Cilobamine in the treatment of atypical depression

✍ Steven Wager; Frederic Quitkin; Jonathan Stewart; Patrick McGrath; Wilma Harriso 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 444 KB

Sixteen patients meeting our criteria for atypical depression were treated in a 7-week single-blind pilot study with cilobamine mesylate, an investigational antidepressant structurally distinct from tricyclic antidepressants (TCA) and monoamine oxidase inhibitors (MAOI). Nine patients (56 per cent)